Form 8-K - Current report:
SEC Accession No. 0001193125-26-202504
Filing Date
2026-05-04
Accepted
2026-05-04 07:05:11
Documents
11
Period of Report
2026-04-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d147392d8k.htm   iXBRL 8-K 25443
  Complete submission text file 0001193125-26-202504.txt   136339

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apls-20260428.xsd EX-101.SCH 3176
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20260428_lab.xml EX-101.LAB 17232
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20260428_pre.xml EX-101.PRE 10809
14 EXTRACTED XBRL INSTANCE DOCUMENT d147392d8k_htm.xml XML 3504
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 26934585
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)